Aditxt

Aditxt Rule of 40

The Rule of 40 of Aditxt (ADTX) as of Oct 25, 2026 is -612,639.84 %. In the previous year, Rule of 40 was -20,875.59 % — a change of 2,834.72% (lower).

Rule of 40

-612,639.84 %

YoY

2,834.72%

Last updated:

Rule of 40 of Aditxt is 2025 -612,639.84 % . Rule of 40 of Aditxt was 2024 -20,875.59 % . It decreases by 2,834.72% lower compared to the previous year.

The Aditxt Rule of 40 history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Rule of 40
Date
Rule of 40
Jan 1, 2022
-1,939.92 USD
Jan 1, 2023
-4,070.49 USD
Jan 1, 2024
-20,875.59 USD
Jan 1, 2025
-612,639.84 USD
The Aditxt Rule of 40 history
YEARRule of 40YoY
-612,639.84 %+2,834.72%
-20,875.59 %+412.85%
-4,070.49 %+109.83%
-1,939.92 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Aditxt Stock analysis

What does Aditxt do? ADiTx Therapeutics, Inc. develops nucleic acid-based technologies for organ transplant tolerance and immune system health. The company's Apoptotic DNA Immunotherapy (ADi) reprograms the immune system to induce tolerance, while Aditxt Immune Monitor (AiM) provides personalized immune profiles. Both technologies are in preclinical development, with the firm focusing on minimizing transplant rejection and addressing autoimmune diseases and allergies. The company is headquartered in Mountain View, California and employs 2 full-time staff. ADiTx Therapeutics, Inc. generates revenue through the development and potential future commercialization of its immune reprogramming and monitoring technologies. The company is a preclinical stage life sciences entity targeting medical applications in organ transplantation and immune-related conditions. Its core products, ADi and AiM, are designed to address unmet medical needs in immune system management. The firm's focus on immune reprogramming and monitoring positions it for potential partnerships with healthcare providers and biopharmaceutical companies in the future. Aditxt is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Aditxt stock

Rule of 40 of Aditxt is -612,639.84 % in 2025.

On Eulerpool you can find the complete historical development of Rule of 40 Aditxt since 2006 – with annual values, charts, and detailed analysis.

The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Quality — Aditxt

AAQSPiotroski F-ScoreAltman Z-ScoreGraham NumberRule of 40

All Key Metrics — Aditxt